Impact Biomedical (IBO) EBITDA Margin (2022 - 2026)

Impact Biomedical (IBO) has reported EBITDA Margin for 3 consecutive years, with 23400.0% the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA Margin fell 695714.0% year-over-year to 23400.0%; the trailing twelve-month figure through Jun 2026 stood at 14540.0% (up 3723895.0% YoY), and the FY2022 full-year result was 6808.0%, changed N/A from the prior year.
• EBITDA Margin improved to 23400.0% in Q2 2026 per IBO's latest filing, from 32700.0% in the prior quarter.
• Across five years, EBITDA Margin topped out at 1500.0% in Q2 2022 and bottomed at 32700.0% in Q1 2026.
• Historically, EBITDA Margin has averaged 15860.79% across 3 years, with a median of 16442.86% in 2025.
• The widest YoY moves for EBITDA Margin: up 695714 bps in 2026, down 695714 bps in 2026.
• Over 3 years, EBITDA Margin stood at 1500.0% in 2022, then plunged by 251 bps to 5261.11% in 2025, then plunged by 345 bps to 23400.0% in 2026.
• According to Business Quant data, EBITDA Margin over the past three periods registered 23400.0%, 32700.0%, and 5261.11% for Q2 2026, Q1 2026, and Q3 2025 respectively.